Exogen Bone Healing System: Efficacy, Uses, and Cost

The Exogen bone healing system is a portable ultrasound device cleared by the FDA to treat fresh fractures and nonunions by delivering low-intensity pulsed ultrasound (LIPUS) through the skin to a fracture site. It operates at 1.5 MHz with an intensity of 30 milliwatts per square centimeter, applied for 20 minutes a day at home. Whether that daily treatment meaningfully speeds bone healing, though, has become one of the more contentious questions in orthopedic medicine. Early trials showed promising reductions in healing time, but more rigorous recent studies have called those findings into serious question, leaving clinicians split on when or whether to prescribe it.

How the Device Works

You strap a small transducer to the skin over your fracture, add a dab of coupling gel, and press a button. The device then sends pulses of low-intensity ultrasound into the underlying bone for exactly 20 minutes. The ultrasound signal is far weaker than what diagnostic imaging uses and generates essentially no heat. Instead, the mechanical pressure waves create micro-scale vibrations that cells in the fracture zone can detect.

At the cellular level, those mechanical vibrations activate a family of surface receptors called integrins on bone-forming and cartilage-forming cells. Once triggered, the integrins kick off a cascade of internal signaling that leads to the production of enzymes and molecules involved in mineralization and the conversion of cartilage into bone, two processes central to how fractures normally heal.¹ The idea is that by gently nudging these pathways every day, the ultrasound treatment supplements the body’s natural repair process without drugs or surgery.

The Early Clinical Promise

The original excitement around Exogen came from two randomized controlled trials conducted in the 1990s. In those studies, patients with fresh tibial shaft fractures and distal radius (wrist) fractures who used the device healed roughly 38 percent faster than patients who received a sham device. In practical terms, that translated to about 58 fewer days to heal for tibial fractures and about 37 fewer days for wrist fractures.² Those results were striking enough to earn FDA clearance and build a large clinical market. For years, Exogen was one of the most widely prescribed bone stimulators in orthopedics.

Those early trials, however, had limitations that became more apparent over time. They were relatively small, the fractures were managed nonoperatively (with casts rather than surgical fixation), and methodological standards have tightened considerably since the 1990s. As the device was adopted more widely, researchers began asking whether the benefits would hold up in larger, more rigorously designed studies.

The Evidence Turned Skeptical

The biggest blow came from the TRUST trial, a large multicenter randomized study published in the BMJ in 2016. It enrolled patients with tibial fractures that had been surgically fixed with an intramedullary nail, the standard modern treatment, and randomly assigned them to receive either LIPUS or an identical-looking sham device. The results were unambiguous: there was no difference in time to radiographic healing between the two groups, and no improvement in functional recovery or quality of life scores.³

A systematic review and meta-analysis published around the same time pooled data from multiple randomized trials and reached a similar conclusion for fresh fractures. When only studies at low risk of bias were considered, LIPUS did not reduce time to weight-bearing, did not reduce pain at four to six weeks, and probably had no meaningful effect on radiographic healing. Studies at higher risk of bias tended to show benefits, while studies at lower risk of bias did not, a pattern that suggests the early positive results may have been artifacts of less rigorous study design.⁴ Return-to-work timelines were also unaffected, and the rate of needing additional surgeries was not significantly lower in the LIPUS group.

This created an uncomfortable split in the literature. The older, smaller trials said the device works. The newer, better trials said it does not, at least for operatively treated fresh fractures. The distinction matters: modern fracture care increasingly involves surgical fixation with nails, plates, and screws, which provide rigid stability that a cast does not. It is plausible that the ultrasound signal adds something when a fracture is managed conservatively in a cast but adds nothing meaningful when a surgeon has already provided robust mechanical stability. That is one interpretation, but it remains speculative.

Where Exogen May Still Have a Role

The sharpest controversy surrounds fresh fractures. For nonunions, fractures that have stopped healing for months, the picture is muddier and somewhat more favorable for the device. A pilot study of 59 patients treated with Exogen for established nonunions reported that patient commitment was essential because the treatment happens entirely at home, but outcomes in compliant patients were encouraging.⁵ A Scottish hospital reported a 94 percent healing rate among patients with long bone nonunions treated with LIPUS, with the best results in a particular subtype called oligotrophic nonunion, where the bone has some blood supply but lacks the biological stimulus to bridge the gap. No serious adverse effects were reported.⁶

But those encouraging numbers are not the whole story. A separate study that carefully followed manufacturer-recommended indications for LIPUS in long bone nonunions found a healing rate of only about 33 percent. The authors described the treatment as resulting in a “clear delay” to definitive management, arguing that the months spent on a device that ultimately failed for most patients could have been spent pursuing surgical revision instead.⁷ That is a meaningful concern: if a nonunion patient spends three to six months on a device that fails two-thirds of the time, they have delayed the surgery they probably needed all along.

How to reconcile a 94 percent healing rate in one study and a 33 percent rate in another? Patient selection is the likely answer. Nonunions vary enormously in their biology, location, gap size, blood supply, and the patient’s overall health. A small cohort at one hospital might skew heavily toward favorable biology, while a different cohort chosen strictly by device labeling might include more challenging cases. The honest conclusion is that LIPUS seems to help some nonunions but fails in many others, and clinicians cannot yet reliably predict which patients will respond.

Fifth Metatarsal Fractures and Anatomical Considerations

One area where more specific evidence exists is the fifth metatarsal, the long bone on the outside edge of the foot. These fractures, especially the notorious Jones fracture at the base of the bone, are prone to nonunion because the area has a relatively poor blood supply. A real-world clinical study using insurance claims data found that patients who completed at least 90 daily Exogen treatments had a meaningfully lower nonunion risk than matched controls who did not use the device. The benefit increased with more treatments: controls had roughly 2.4 times the nonunion risk compared to patients who completed 120 or more sessions, and five times the risk compared to those who completed 140 or more.⁸

Among Jones fracture patients specifically, the nonunion rate was cut by more than half in compliant users, though that particular finding only approached statistical significance. Still, for a fracture type that frequently fails to heal and often requires surgery, even suggestive evidence of benefit carries practical weight. Orthopedic surgeons who prescribe Exogen most confidently tend to favor it for exactly this kind of situation: a fracture in a location known to be slow-healing, where the alternative is a second surgery.

Compliance Is the Bottleneck

Because Exogen is a home-use device, treatment only works if you actually do it. Twenty minutes a day, every day, for weeks or months, is a bigger ask than it sounds. The device tracks usage internally, and the data paint a clear picture: compliance tends to drop over time. With an earlier-generation Exogen device, average compliance was about 74 percent, and in some periods it fell as low as 51 percent. A redesigned version with a built-in calendar display and other usability improvements raised overall compliance to about 84 percent and prevented it from dropping below 76 percent.⁹ A literature review cited in that same study found that compliance rates above 70 percent are correlated with better clinical effectiveness, so the design changes were not just cosmetic.

This compliance issue may partly explain why real-world outcomes vary so much. In a clinical trial, patients are monitored and reminded. In the real world, a patient with a sore foot and a busy schedule may skip sessions, and the device on the nightstand gradually becomes furniture. If you are prescribed Exogen, treating it like a daily medication rather than an optional add-on is probably the most important thing you can do to give it the best chance of working.

Who Might Benefit Most

A narrative review that examined both the positive and negative studies concluded that the patients most likely to benefit from LIPUS are those already at elevated risk for healing problems, specifically older adults and people with diabetes.¹⁰ The logic is intuitive: if your biology is already compromised in ways that slow bone repair, adding a stimulus might push you past a threshold that a healthy young person’s body crosses on its own. In someone with normal healing capacity, the ultrasound signal may be redundant.

A large cohort study of over 4,000 patients treated with LIPUS confirmed that several risk factors, including open fracture, smoking, diabetes, vascular insufficiency, osteoporosis, cancer, rheumatoid arthritis, and use of anti-inflammatory drugs, all reduced healing speed. Interestingly, patients aged 60 and older responded to LIPUS at rates similar to the overall population, suggesting that age alone did not make the device less effective.¹¹ That is reassuring if you are older and considering the device, but it is worth noting that this was an observational cohort without a control group, so it demonstrates that older patients can heal with LIPUS rather than proving the device itself caused the healing.

How Exogen Compares to Other Bone Stimulators

Exogen is not the only bone growth stimulator on the market. Pulsed electromagnetic field (PEMF) devices are another option, and some clinicians use direct-current electrical stimulation as well. The mechanisms differ: Exogen uses mechanical sound waves, while PEMF devices use electromagnetic pulses to induce tiny electrical currents in bone tissue. At the cellular level, lab studies show that LIPUS and PEMF trigger somewhat different responses. LIPUS tends to produce a rapid, short-lived protein response in bone cells, while PEMF effects are delayed but may influence different molecular pathways related to bone turnover.¹²

Clinically, neither technology has a clear edge over the other. A systematic review and meta-analysis that pooled results from 13 trials found no significant difference in nonunion rates between patients who received either PEMF or LIPUS and control patients. Both technologies showed some acceleration of time to healing in non-operatively treated fractures and upper-limb fractures, but neither proved superior overall.¹³ The choice between Exogen and a PEMF device often comes down to physician preference, insurer coverage, and fracture location rather than strong evidence favoring one over the other.

Safety and Precautions

For adults, Exogen has a reassuring safety record. Across multiple studies, serious adverse effects directly attributable to the device are essentially absent. The ultrasound intensity is low enough that it does not heat tissue or cause pain. Most patients describe the treatment as feeling like nothing at all, or occasionally a mild warmth or tingling.

The main safety concern involves children and adolescents. Growth plates, the cartilage zones near the ends of long bones where growth occurs, are sensitive to mechanical stimulation. A systematic review on the effects of therapeutic ultrasound around growth plates found no reports of growth disturbance in humans, but animal studies did show histological changes in the growth plate tissue. Based on those findings, the recommendation is to avoid applying ultrasound near the growth plate in young patients.¹⁴ This does not mean children can never use LIPUS, but the transducer placement needs to be carefully considered by the prescribing physician to avoid the physis.

Other standard contraindications include not applying the device over an active infection, directly over hardware that might concentrate the ultrasound energy, or over areas with known malignancy. These are largely precautionary and based on theoretical risks rather than documented adverse events.

Cost and Insurance Considerations

Exogen is not cheap. Without insurance, the device can run several thousand dollars. For nonunions, many insurers cover it because the alternative, revision surgery, is substantially more expensive. A health technology assessment by the Norwegian Institute of Public Health found that when used for nonunions, Exogen was potentially “dominant,” meaning it was both cheaper and more effective compared to surgical treatment in the base-case analysis. The cost advantage narrowed as the assumed success rate of surgery improved, but even in those scenarios Exogen remained considerably less expensive as a first-line attempt.¹⁵

For fresh fractures, the cost-effectiveness picture is shakier because the evidence that it helps at all in that setting has weakened so much. Some insurers have pulled coverage for fresh fracture indications while maintaining it for nonunions. If your surgeon prescribes it, checking with your insurer before starting is worth the phone call, as coverage varies widely.

Effects Beyond Bone

Researchers have also investigated whether the ultrasound signal from LIPUS affects soft tissues around a fracture site. In animal studies, the same type of low-intensity pulsed ultrasound used by Exogen improved healing at bone-tendon junctions. A rabbit study found that LIPUS treatment produced thicker cartilage zones and more advanced tissue development at the healing interface, with increased expression of a growth factor that drives blood vessel formation in the area.¹⁶ A separate rabbit study found that the hardness of newly formed tissue at the bone-tendon junction, including fibrocartilage and healing tendon, was significantly greater in the LIPUS group by 16 weeks.¹⁷

In a canine study looking at cartilage repair, LIPUS-treated sites showed improved gross appearance and better histologic quality of the repair tissue compared to untreated sites, with improved bonding between a transplanted cartilage plug and the surrounding tissue.¹⁸ These are animal findings and have not been confirmed in human clinical trials for soft tissue indications, so they remain scientifically interesting rather than clinically actionable. But they suggest the device’s biological effects are not limited strictly to bone cells.

Orthodontic and Veterinary Research

In a somewhat unexpected application, researchers have tested Exogen in a rabbit orthodontic model to see whether LIPUS could reduce tooth relapse after orthodontic movement. The idea is that stimulating bone formation in the socket might help teeth stay in their new positions. In that study, rabbits receiving LIPUS showed about 35 percent less relapse in tooth position by day 20 compared to controls, with the difference becoming statistically significant from day 10 onward.¹⁹ This is early-stage animal research with no direct clinical application yet, but it illustrates how the same fundamental mechanism, stimulating bone cells through mechanical vibration, can be applied to problems well outside traditional orthopedic fracture care.

Veterinary medicine has begun exploring LIPUS for similar reasons. Fracture nonunion is a meaningful problem in companion animals, particularly dogs, and the same biological principles apply. Commercial veterinary use remains limited, but the animal model data that supports human applications was, by definition, conducted in animals and demonstrates that the effect crosses species lines. If LIPUS gains traction in veterinary orthopedics, it will likely follow the same pattern seen in human medicine: strongest enthusiasm among clinicians who treat difficult, slow-healing cases, with skepticism from those who see most fractures heal well on their own with good surgical technique.